AcquisitionOther
Yarrow Bioscience, Inc. acquired VYNE Therapeutics Inc
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Yarrow Bioscience, Inc. -> VYNE Therapeutics Inc
To combine and advance YB-101, a potentially first-in-class TSHR antibody for Graves' disease and thyroid eye disease.
Open source record (SEC) ↗